As of January 26, 2023, the FDA announced the product, Evusheld (M0220) is NOT authorized for use in any US region and may not be administered until further notice.
As of June 6, 2021, West Virginia Medicaid will reimburse the administration of Covid-19 monoclonal antibody treatments, billed with M0243, M0245 and M0247 at the Medicare rate of $450.00.
Update!
Due to the high frequency of the Omicron BA.2 sub-variant, the Federal Drug Administration (FDA) announced the product, Sotrovimab (procedure code M0247), is currently NOT authorized in any U.S. region and may not be administered to treat COVID-19 until further notice by the FDA.